Drug Approval | October 04, 2021
Biocon launches Everolimus tablets in the US
According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021
According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
It’s an AB-rated generic therapeutic version of Durezol
A veteran in cell therapy and oncology commercialisation
Subscribe To Our Newsletter & Stay Updated
